X-Energy Just Went Public in 2026. Here's How It Stacks Up Against Oklo, NuScale, and BWX Technologies.

X-Energy trades near $14 per share, almost 40% below its $23 April IPO price, despite projected 2026 revenue growth of 94% to $212 million. The company posted a $390 million net loss in 2025 and is expected to widen its loss to $430 million in 2026, while its $4.1 billion valuation equates to roughly 19x forward sales. Regulatory uncertainty around its TRISO-fueled high-temperature reactor design, fuel-supply scaling needs, commercial deployment not expected until the early 2030s, and higher Treasury yields are cited as key risks; the article favors BWX Technologies as a more resilient alternative.

Analysis

XE's relevant valuation is not against current engineering revenue but against the probability-weighted value of an NRC-approved reactor-plus-fuel ecosystem. The market is likely to keep discounting that value until there is a concrete licensing milestone and evidence that TRISO-X can produce qualified fuel at commercial scale; the intervening capital needs create a dilution overhang that a lower share price alone does not solve. A 1-3 month move will remain dominated by real yields and retail/speculative nuclear sentiment rather than fundamentals.

BWXT is the cleaner beneficiary of nuclear spending because it monetizes existing defense, fuel, and component capacity while SMR developers consume cash. More subtly, any difficulty commercializing advanced fuel increases the strategic value of established nuclear-fuel fabrication and qualified-component supply chains, potentially supporting BWXT's multiple even if first-of-a-kind SMR timelines slip. SMR and OKLO have regulatory optionality, but their equity values similarly require years of financing before operating cash flow; their correlation to XE should rise during rate shocks despite differing technologies.

Contrarianly, the selloff is not necessarily a signal that XE's technology is impaired: a customer-funded milestone, DOE fuel award, or NRC acceptance of a licensing pathway could reprice the equity sharply because its valuation embeds a long-duration option. But that is an event-driven thesis, not a value thesis. The key falsifiers are a further widening of annual cash burn without offsetting contracted funding, delayed licensing submissions, or evidence that fuel qualification/yields prevent a credible commercial cost curve.

AMZN's exposure should not be traded on this development alone: its power-procurement strategy creates optionality but is immaterial to consolidated earnings. The more actionable read-through is that hyperscaler demand can support multiple nuclear pathways, yet it does not eliminate execution risk for any individual reactor vendor.

Key Decisions for Investors

• Maintain/establish long BWXT versus short XE in equal dollar amounts over a 6-12 month horizon. The pair isolates execution and financing risk in advanced reactors against an incumbent with nearer-term cash generation; reassess if XE secures NRC design-certification progress plus externally funded fuel-capacity expansion.
• Avoid initiating a directional XE long solely on the post-IPO decline. Upgrade to a tactical long only after verified licensing acceptance or a binding, funded fuel/offtake agreement; size as a high-volatility event position with a 3-6 month horizon, not a core holding.
• For nuclear-beta exposure, prefer BWXT over SMR and OKLO until long-duration yields decline materially or those issuers disclose funded construction pathways. A sustained decline in 10-year Treasury yields would be the principal catalyst for a broad SMR valuation rerating and the main risk to the BWXT/XE pair.
• Set alerts around XE quarterly cash burn, committed backlog conversion, and TRISO-X production qualification. A material capital raise before these milestones would reinforce the short leg; funded progress without major dilution would invalidate it.